DYN

Dyne Therapeutics Inc. Common Stock (DYN)

Stock · NASDAQ · Health Care

$14.25as of 10/16/2026

AI Market Commentary

AI-generatedAll commentary →

Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.

October 10, 2026

Dyne Therapeutics highlighted in recent healthcare stock coverage. Dyne Therapeutics appeared in a Benzinga pre‑market roundup of 12 health‑care stocks. Yahoo highlighted the company in a piece about why it is back in the spotlight, and Raymond James analysts listed it among four health‑care stocks they back. The coverage brings renewed attention to DYN as it trades near its recent support level.

Price chart

Open in TradingView

Active signals

BOLL Breakdown76.9%200 SMA Touch0.0%
Resistance level
$18.15
Industry
Biotechnology: Pharmaceutical Preparations

DYN Signal Track Record

How signals performed across all stocks →

What DYN's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.

SignalTimesMedian 20-session returnHigher after 20 sessions
Volume Spike40+2.4%53%
Bollinger Band Breakout27+7.6%63%
Bollinger Band BreakdownActive now19+8.1%63%
200-Day Moving Average TouchActive now11+18.0%73%
Any 20-session window (baseline)+1.4%52%

Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.

About DYN

Dyne Therapeutics, Inc., a clinical-stage neuromuscular disease company, focuses on discovering and developing therapeutics for neuromuscular diseases in the United States. The company is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; facioscapulohumeral dystrophy; and Pompe disease, as well as rare skeletal muscle, and cardiac and…

Sector
Health Care
Industry
Biotechnology: Pharmaceutical Preparations
Employees
289

Fundamentals

1-day range
$14.3$15.49
Market cap
$4.83B
P/E (trailing)
—
P/E (forward)
-4.29
EPS (trailing)
$-3.33
Dividend yield
—
Beta
1.25
Avg. volume
2.93M
52-week range
$13.88$27.31
Next earnings: November 5, 2026 · EPS estimate $-0.89confirmed

Forecasts

15 analyst ratings

Buy 91%
Hold 10%
Sell 0%
1-year price forecast
High
$50
+250.9%
Median
$37
+159.6%
Low
$10
-29.8%

Dyne Therapeutics Inc. Common Stock Competitors

Chosen by industry and closest market cap.

  • DYN
    Dyne Therapeutics Inc. Common Stock
    $14.25
    ▼ 6.80%
    Market cap $4.83BP/E —
    $13.88$27.31
  • INDV
    Indivior Pharmaceuticals Inc. Common Stock
    $32.45
    ▼ 3.48%
    Market cap $4.82BP/E 11.25
    $23.67$42.81
  • ACAD
    ACADIA Pharmaceuticals Inc. Common Stock
    $19.12
    ▼ 2.99%
    Market cap $4.87BP/E 8.79
    $18.39$30.96
  • EWTX
    Edgewise Therapeutics Inc. Common Stock
    $37.19
    ▼ 2.64%
    Market cap $4.78BP/E —
    $14.25$48.51
  • MANE
    Veradermics Incorporated Common Stock
    $108.82
    ▼ 5.43%
    Market cap $4.54BP/E —
    $32$136.72
  • GRFS
    Grifols S.A. American Depositary Shares
    $7.64
    ▲ 1.33%
    Market cap $5.38BP/E 12.88
    $8.43$12.15
  • PBLS
    Parabilis Medicines Inc. Common Stock
    $22.75
    ▼ 9.65%
    Market cap $4.23BP/E —
    $24.51$42.49

P/E shows — for peers not currently carrying a live signal of their own.

Latest news

Insider Activity

Insider Actions →
Acquired
2.5K
Disposed
2.60M

Institutional Ownership

March 31, 2026

Total shares held
179.59M
Total value held
$2.64B
Institutional holders
221
Top holders this quarter
  • Unknown30.79M
  • Unknown13.65M
  • Unknown11.70M
  • Unknown9.13M
  • Unknown8.91M
  • Unknown6.76M
  • Unknown6.65M
  • Unknown6.41M
  • Unknown4.67M
  • Unknown4.64M

See the full, filterable feed with live charts on the MarketWall dashboard.

We use analytics to understand how market-wall is used. No personal data is sold.